Would you consider first line FOLFOXIRI and cetuximab or panitumumab for physically fit patients with metastatic RAS/BRAF WT colon cancer?
Instead of FOLFOXIRI and bevacizumab as per TRIBE trial
Answer from: Medical Oncologist at Community Practice
The VOLFI study is a phase II trial comparing modified FOLFOXIRI plus panitumumab to mFOLFOXIRI. The study showed an improved overall response rate (ORR) of 87.3% v 60.6% (odds ratio, 4.469; 95% CI, 1.61 to 12.38; P = .004). The secondary resection rate was also improved with the addition of panitum...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I do use FOLFOXIRI plus PANI when I desperately need tumor shrinkage to take the patient for a resection. However, I make sure the tumor is HER2’ non-amplified apart from being left-sided and RAS/RAF wild type. I also give 5FU 2,400 mg per meter square dose because if you look at the dose dens...
Answer from: Medical Oncologist at Academic Institution
The decision would depend on the sidedness of the primary tumor. Based on the PARADIGM study result (combined with phase III CALGB/SWOG 80405 trial, FIRE-3 study, and meta-analysis result, etc), for left sided primary KRAS/NRAS/BRAF WT metastatic colorectal cancer, it will be very reasonable to cons...
Answer from: Medical Oncologist at Academic Institution
No, at this point I am only utilizing FOLFOXIRI with Bevacizumab in triplet-eligible patients on the basis of the randomized Phase III TRIPLETE trial presented at ASCO Annual Meeting 2022. That study randomized newly diagnosed RAS/BRAF wild type patients to receive either 1L FOLFOXIRI/Panitumumab or...
Answer from: Medical Oncologist at Academic Institution
Triplet chemotherapy, FOLFOXIRI, is increasingly recommended and used based on the data from GONO group. Use of triplet therapy results in improved response rate, PFS, and OS. Expectedly, the additional benefit observed with the triplet regimen comes with increased toxicities (Falcone et al., PMID 1...